Biosimilars in inflammatory bowel disease

Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

Research output: Contribution to journalComment / DebateOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)294-295
Number of pages2
JournalMedical Journal of Australia
Volume205
Issue number7
DOIs
Publication statusPublished - 3 Oct 2016

Cite this

@article{60a9f2c5f09e4cafa879543dd944733e,
title = "Biosimilars in inflammatory bowel disease: Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited",
author = "Moore, {Gregory T}",
year = "2016",
month = "10",
day = "3",
doi = "10.5694/mja16.00775",
language = "English",
volume = "205",
pages = "294--295",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "AMPCo",
number = "7",

}

Biosimilars in inflammatory bowel disease : Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited. / Moore, Gregory T.

In: Medical Journal of Australia, Vol. 205, No. 7, 03.10.2016, p. 294-295.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Biosimilars in inflammatory bowel disease

T2 - Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

AU - Moore, Gregory T

PY - 2016/10/3

Y1 - 2016/10/3

UR - http://www.scopus.com/inward/record.url?scp=85016924779&partnerID=8YFLogxK

U2 - 10.5694/mja16.00775

DO - 10.5694/mja16.00775

M3 - Comment / Debate

VL - 205

SP - 294

EP - 295

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - 7

ER -